Vilin Bio Med SME IPO

Vilin Bio Med Limited

₹1,20,000 /4000 sharesMinimum Investment

Vilin Bio Med SME IPO Listing Details

Listed OnIssue PriceListing PriceListing Gains
NSE₹30.00₹29.00-₹1.00 (3.33%)

Vilin Bio Med SME IPO Details

Bidding DatesMin. InvestmentLot SizePrice Range
16 Jun ‘23 - 21 Jun ‘23₹1,20,0004,000₹30 - ₹30
Issue SizeIPO Doc
12.00Cr
RHP PDF

About Vilin Bio Med SME

Vilin Bio Med was incorporated on June 29, 2005. The company operates in the pharmaceutical sector, focusing on the domestic market. Its manufacturing facility is situated in Roorkee, Uttarakhand. The company primarily engages in bulk sales to pharmaceutical manufacturers, marketers, and traders, who serve as the distribution channel for customers. These products, which include oral liquid formulations such as syrups, suspensions, and dry powders, as well as tablets, capsules, and external preparations, are predominantly utilized by pharmaceutical companies and traders. Eventually, these entities distribute and market the products to distributors and retail customers. ;
Parent Organisation
Vilin Bio Med Limited
Founded
2005
Managing Director
Mr Viswa Prasad Sadhanala

Strengths & Risks

  • Vilin Bio Med has a testing laboratory within its manufacturing unit to ensure the quality of its products.
  • The products undergo thorough quality checks to meet both domestic and international standards. The in-house testing laboratory also ensures that the products meet specific customer requirements.
  • The company currently operates at only 30% capacity, leaving significant room for growth.
  • By scaling up production and utilizing the remaining 70% capacity, they aim to take advantage of economies of scale. It may lead to lower operational costs and increased profit margins.
  • Vilin Bio Med has implemented manufacturing standards to achieve consistent product quality across all markets.
  • The company is currently facing legal proceedings that have the potential to negatively impact its business, financial condition, and operational results.
  • The company's revenue heavily depends on its top 10 customers, who accounted for a significant portion of the revenue in recent periods.
  • The company does not own the registered office from which it operates.
  • The company has obtained unsecured loans from the promoters and promoter group, which the lenders can recall at any time. As of December 31, 2022, the outstanding amount of these loans was Rs 108.24 lakh.
  • The company has experienced negative cash flows and any future occurrences could adversely affect its business, operations, and prospects.

Financials

*All values are in Rs. Cr
No Graph Data To Display

Application details

Apply asPrice bandApply upto
Regular30 - 30₹2 Lakh
High Networth Individual30 - 30₹2 - 5 Lakh
For Vilin Bio Med SME IPO, eligible investors can apply as Regular.
ⓒ 2016-2023 Groww. All rights reserved, Built with in India
MOST POPULAR ON GROWWVERSION - 4.5.1
STOCK MARKET INDICES:  S&P BSE SENSEX |  S&P BSE 100 |  NIFTY 100 |  NIFTY 50 |  NIFTY MIDCAP 100 |  NIFTY BANK |  NIFTY NEXT 50
MUTUAL FUNDS COMPANIES:  GROWWMF |  SBI |  AXIS |  HDFC |  UTI |  NIPPON INDIA |  ICICI PRUDENTIAL |  TATA |  KOTAK MAHINDRA |  DSP |  CANARA ROBECO |  SUNDARAM |  MIRAE ASSET |  BANDHAN |  FRANKLIN TEMPLETON |  PPFAS |  MOTILAL OSWAL |  INVESCO |  EDELWEISS |  ADITYA BIRLA SUN LIFE |  LIC |  HSBC |  NAVI |  QUANTUM |  UNION |  IDBI |  ITI |  MAHINDRA MANULIFE |  360 ONE |  BOI |  TAURUS |  JM FINANCIAL |  PGIM |  SHRIRAM |  BARODA BNP PARIBAS |  QUANT |  WHITEOAK CAPITAL |  TRUST |  SAMCO |  NJ |  BAJAJ

ABOUT GROWW